Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice

Background: The use of oral corticosteroids (CS) is one of the most common causes of iatrogenic osteoporosis. Recently, therapeutic guidelines dealing with the skeletal complication of CS have been published. Objective: To evaluate how CS are used in the community and the frequency of active interve...

Full description

Bibliographic Details
Published in:Annals of the Rheumatic Diseases
Main Authors: Gudbjornsson, B, Juliusson, U I, Gudjonsson, F V
Format: Text
Language:English
Published: BMJ Publishing Group Ltd 2002
Subjects:
Online Access:http://ard.bmj.com/cgi/content/short/61/1/32
https://doi.org/10.1136/ard.61.1.32
id fthighwire:oai:open-archive.highwire.org:annrheumdis:61/1/32
record_format openpolar
spelling fthighwire:oai:open-archive.highwire.org:annrheumdis:61/1/32 2023-05-15T16:52:14+02:00 Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice Gudbjornsson, B Juliusson, U I Gudjonsson, F V 2002-01-01 00:00:00.0 text/html http://ard.bmj.com/cgi/content/short/61/1/32 https://doi.org/10.1136/ard.61.1.32 en eng BMJ Publishing Group Ltd http://ard.bmj.com/cgi/content/short/61/1/32 http://dx.doi.org/10.1136/ard.61.1.32 Copyright (C) 2002, BMJ Publishing Group Ltd Extended reports TEXT 2002 fthighwire https://doi.org/10.1136/ard.61.1.32 2015-02-28T20:38:08Z Background: The use of oral corticosteroids (CS) is one of the most common causes of iatrogenic osteoporosis. Recently, therapeutic guidelines dealing with the skeletal complication of CS have been published. Objective: To evaluate how CS are used in the community and the frequency of active intervention against corticosteroid induced osteoporosis in daily clinical practice. Material and methods: After approval by the Committee on Medical Ethics and the Data Protection Commission all prescriptions for CS which were filled by pharmacies in the northeast area of Iceland (population 26 664) during a two year period were collected. Thereafter, clinical information was obtained from medical records at the healthcare centres and from the local hospital. Patients who were taking CS for at least three months a year or for repeated periods (for a total of three months annually) were included in the study. These patients also received a questionnaire about hormone replacement therapy, bisphosphonates, and dietary consumption of calcium and vitamin D. Results: A total of 191 patients were included in the study or 0.7% of the population. Their mean age was 66 years (17–93) and 106/191 (55%) were women. Only 63 (33%) patients had no registered complication due to the treatment, according their medical records. Thirty nine (20%) patients had had an osteoporosis related fracture and 50 (26%) of the patients had presumed CS induced osteoporosis. A total of 52% patients were receiving supplementary vitamin D (fish liver oil) and 37% were taking calcium tablets regularly, while 91% of the patient group were consuming milk products regularly. Only 17 (9%) patients were taking bisphosphonates and 18/81 (22%) of the postmenopausal women were receiving hormone replacement therapy. Conclusions: Relatively few patients receiving long term treatment with CS are also receiving primary prevention against CS induced osteoporosis, although several patients are taking vitamin D and calcium tablets. Specific treatment against osteoporosis was ... Text Iceland HighWire Press (Stanford University) Annals of the Rheumatic Diseases 61 1 32 36
institution Open Polar
collection HighWire Press (Stanford University)
op_collection_id fthighwire
language English
topic Extended reports
spellingShingle Extended reports
Gudbjornsson, B
Juliusson, U I
Gudjonsson, F V
Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice
topic_facet Extended reports
description Background: The use of oral corticosteroids (CS) is one of the most common causes of iatrogenic osteoporosis. Recently, therapeutic guidelines dealing with the skeletal complication of CS have been published. Objective: To evaluate how CS are used in the community and the frequency of active intervention against corticosteroid induced osteoporosis in daily clinical practice. Material and methods: After approval by the Committee on Medical Ethics and the Data Protection Commission all prescriptions for CS which were filled by pharmacies in the northeast area of Iceland (population 26 664) during a two year period were collected. Thereafter, clinical information was obtained from medical records at the healthcare centres and from the local hospital. Patients who were taking CS for at least three months a year or for repeated periods (for a total of three months annually) were included in the study. These patients also received a questionnaire about hormone replacement therapy, bisphosphonates, and dietary consumption of calcium and vitamin D. Results: A total of 191 patients were included in the study or 0.7% of the population. Their mean age was 66 years (17–93) and 106/191 (55%) were women. Only 63 (33%) patients had no registered complication due to the treatment, according their medical records. Thirty nine (20%) patients had had an osteoporosis related fracture and 50 (26%) of the patients had presumed CS induced osteoporosis. A total of 52% patients were receiving supplementary vitamin D (fish liver oil) and 37% were taking calcium tablets regularly, while 91% of the patient group were consuming milk products regularly. Only 17 (9%) patients were taking bisphosphonates and 18/81 (22%) of the postmenopausal women were receiving hormone replacement therapy. Conclusions: Relatively few patients receiving long term treatment with CS are also receiving primary prevention against CS induced osteoporosis, although several patients are taking vitamin D and calcium tablets. Specific treatment against osteoporosis was ...
format Text
author Gudbjornsson, B
Juliusson, U I
Gudjonsson, F V
author_facet Gudbjornsson, B
Juliusson, U I
Gudjonsson, F V
author_sort Gudbjornsson, B
title Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice
title_short Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice
title_full Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice
title_fullStr Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice
title_full_unstemmed Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice
title_sort prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice
publisher BMJ Publishing Group Ltd
publishDate 2002
url http://ard.bmj.com/cgi/content/short/61/1/32
https://doi.org/10.1136/ard.61.1.32
genre Iceland
genre_facet Iceland
op_relation http://ard.bmj.com/cgi/content/short/61/1/32
http://dx.doi.org/10.1136/ard.61.1.32
op_rights Copyright (C) 2002, BMJ Publishing Group Ltd
op_doi https://doi.org/10.1136/ard.61.1.32
container_title Annals of the Rheumatic Diseases
container_volume 61
container_issue 1
container_start_page 32
op_container_end_page 36
_version_ 1766042392247402496